Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 03 Oct 2025 | Olga Solomon Head of Unit | The discussion focused on simplifying Annex II to foster innovation while aligning with ICH guidelines, with ideas for legacy products to gradually transition. | — |
| 03 Oct 2025 | Olga Solomon Head of Unit | The discussion focused on simplifying Annex II to foster innovation while aligning with ICH guidelines, with ideas for legacy products to gradually transition. | SRC |
Mission & Goals
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in over 100 countries. In financial year 2024, STADA achieved group revenues of € 4,059 million and adjusted constant-currency earnings before interest, taxes, depreciation and amortization (adj. cc EBITDA) of € 886 million. As of 31 December 2024, STADA employed 11,649 people worldwide.
EU Legislative Interests
EU Pharma Legislation Review, including intellectual property provisions, trade, public health and access to medicines Critical Medicines Act Urban Wastewater Directive
Communication Activities
Supporting Medicines for Europe outreach on medicines access
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Medicines for Europe and constituent national off-patent medicines associations (https://www.medicinesforeurope.com/)
Organisation Members
National chambers of commerce e.g. in Germany, Serbia
Additional Information
No EU-level intermedaries used